{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-22-000019","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.460755+00:00","generated_at":"2026-06-22T03:44:19.266911+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Caribou Q3 net loss $26.6M, cash $342.6M; CB-011 IND submitted, CB-010 ODD for FL","bullets":["Net loss $26.6M vs $21.0M YoY; revenue $3.3M (down from $4.0M) on lower AbbVie collaboration revenue.","Cash, cash equivalents, and marketable securities $342.6M as of Sept 30, 2022, down from $413.5M at Dec 31, 2021.","CB-010 ANTLER Phase 1 trial enrolling at dose level 2; ODD for follicular lymphoma granted Sept 2022.","CB-011 IND for relapsed/refractory multiple myeloma submitted to FDA in Q4 2022; FDA response expected by YE 2022.","CB-012 IND for r/r AML expected in 2023; CB-020 target selection for CAR-NK solid tumors expected Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-22-000019","json":"https://secwatch.observer/filing/0001619856-22-000019.json","markdown":"https://secwatch.observer/filing/0001619856-22-000019.md","text":"https://secwatch.observer/filing/0001619856-22-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985622000019/0001619856-22-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985622000019/crbu-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:44:19.266911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81f8cc5ed72119d265eb2763b5fce0fb9cf87a12","claim":"Caribou Biosciences, Inc. reported the third quarter of 2022 results: revenue $3.3 million, net income $26.6 million.","evidence_excerpt":"of September 30, 2022, compared to $413.5 million as of December 31, 2021. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.3 million for the three months ended September 30, 2022, compared to $4.0 million for the same period in 2021. The decrease was primarily due to a decrease in revenue under the AbbVie","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985622000019/0001619856-22-000019-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"$3.3 million"},{"label":"Net income","value":"$26.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}